Sun Pharmaceutical Industries Limited
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS6
PHASE 3 / 2-34
RECRUITING2
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO80%
Delay Index: of 5 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +30.0 months). See all sponsors →
Open Sun Pharmaceutical Industries Limited on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Tildrakizumab NCT03997786 |
P2/3 | Active, not recruiting | Moderate-to-severe Chronic Plaque Psoriasis | 135 | 2025-04-07 (+17 mo) |
| TILD NCT04314531 |
P3 | Active, not recruiting | Active Psoriatic Arthritis | 296 | 2025-06-04 (+49 mo) |
| Tildrakizumab 100 mg NCT06611163 |
P3 | Active, not recruiting | Moderate to Severe Genital Psoriasis | 206 | 2026-01-21 (+2 mo) |
| GL0034 Dose Level 1 NCT07282743 |
P2 | Recruiting | Type II Diabetes Mellitus | 285 | 2027-04 |
| Abiraterone acetate NCT05422911 |
P2 | Recruiting | Metastatic Cancer; Neoplasm, Prostate | 192 | 2027-12-31 (+30 mo) |
| TILD sub-cutaneous (SC) injection NCT04991116 |
P3 | Active, not recruiting | Psoriatic Arthritis | 529 | 2028-12 (+60 mo) |